1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

‘Important Steps To Ensure Equitable Care’: Medtronic Exec On Pulse Ox Panel

 
• By Elizabeth Orr

Sam Ajizian, chief medical officer of Medtronic’s patient monitoring operating unit, spoke to Medtech Insight about his reaction to a recent FDA panel meeting on ways to improve pulse oximetry accuracy and equity.

Caregiver securing pulse oximeter on the hand of a Black patient.
• Source: Shutterstock

A plan put forward by the US Food and Drug Administration and supported by most participants in a 2 February meeting of the agency’s anesthesiology and respiratory therapy devices advisory panel would more than double the minimum sample size needed in pulse oximeter clinical trials, as well as increasing the need for representation of people with darker skin tones. The move could be an important step for health equity, but what will it mean for device manufacturers?

Sam Ajizian, chief medical officer of Medtronic’s patient monitoring operating unit, spoke to Medtech Insight about his reaction to the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

EU Authorities Unite In Call For Urgent Overhaul Of Medtech Regulations

 
• By Amanda Maxwell

EU member states have issued a consensus statement on the urgent need to build momentum to tackle governance and centralization issues as part of much-needed reform of the EU medtech regulatory system.

Whoops! FDA Says Company Marketed Unauthorized Device. The Company Says The FDA Is Wrong

 
• By Brian Bossetta

A recent FDA warning letter claims a Boston firm that specializes in wearable technology marketed a blood pressure device without agency approval. The company rejects the assertion and says the agency is out of step with federal law.

With CMS Coverage Established, Medtronic Looks To Next Steps For Renal Denervation

 
• By Elizabeth Orr

US Medicare has proposed national coverage of renal denervation for patients with uncontrolled hypertension. The treatment is seeing other advances as well, with Medtronic piloting a longer catheter and a multi-organ approach and a blood test to identify the best candidates fresh on the

Burden Is Too Heavy For Medtechs To Go It Alone On Complex Medtech AI Projects

 
• By Amanda Maxwell

Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.

More from Policy & Regulation

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

 
• By Brian Bossetta

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

Warning Letters – June 2025

The US FDA posted eight device-related warning letters in June, touching on industry sectors from urinalysis test strips to ophthalmic devices.

Study: FDA’s Breakthrough Path Speeds Access, But Raises Safety Questions

 
• By Elizabeth Orr

Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.